Drug Search Results
More Filters [+]

AERAS-422

Alternative Names: aeras-422, aeras422, aeras 422
Latest Update: 2012-08-16
Latest Update Note: Clinical Trial Update

Product Description

We report a first-in-human trial evaluating safety and immunogenicity of a recombinant BCG, AERAS-422, over-expressing TB antigens Ag85A, Ag85B, and Rv3407 and expressing mutant perfringolysin. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/27322481/)

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Vaccine

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Aeras
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AERAS-422

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Tuberculosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

C-007-422

P1

Completed

Tuberculosis

2012-02-01

Recent News Events

Date

Type

Title